Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?

Valneva SE (NASDAQ:VALN)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $8.33, but opened at $7.90. Valneva shares last traded at $7.71, with a volume of 84,288 shares traded.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Valneva in a research note on Friday, January 31st.

Valneva Stock Down 5.1 %

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The stock has a 50 day simple moving average of $4.79 and a 200 day simple moving average of $5.65. The firm has a market capitalization of $642.36 million, a PE ratio of -60.92 and a beta of 1.98.

Hedge Funds Weigh In On Valneva

A number of large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after purchasing an additional 30,859 shares during the period. AlphaCentric Advisors LLC increased its stake in shares of Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after buying an additional 29,748 shares during the period. Finally, ABC Arbitrage SA purchased a new position in shares of Valneva during the fourth quarter valued at approximately $84,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.